News about Merck

Refine your search with the following facets to narrow down your results.

446 Current news of Merck

Q1 Results: Merck Benefits from Global Diversification in a Challenging Environment

Medium-term structural growth drivers intact

12-May-2023 - Merck generated net sales of €5.3billion in the first quarter of 2023. This corresponds to an increase of 1.8% over the year-earlier quarter (organically 0.8%). Sales growth was in particular attributable to Healthcare, which delivered significant increases in its business with new medicines, ...

Merck quarterly reports

Merck chief financial officer steps down

Helene von Roeder appointed Chief Financial Officer and Executive Board Member, effective July 1, 2023

09-May-2023 - Marcus Kuhnert has decided to step down as Chief Financial Officer and Member of the Executive Board of Merck as of June30,2023. He will continue to serve as a Member of the Executive Board of E.MerckKG until July 31, 2024. The Board of Partners of E. Merck KG has appointed Helene von Roeder ...

Marcus Kuhnert Merck personnel changes

Fiscal 2022: Merck Delivers Profitable Growth Despite Challenges

Forecast for 2023: further growth in net sales expected despite increasing headwinds

02-Mar-2023 - Merck delivered profitable growth despite challenges in fiscal 2022. Group net sales increased by 12.9% (organically: 6.4%) to €22,232million compared with the previous year. Sales growth was driven by all regions and business sectors, particularly Life Science. The Big 3 businesses – Process ...

fiscal year Merck

Merck Announces Collaboration With Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory and commercial milestones, as well as royalties on net sales

27-Dec-2022 - Merck announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets. ...

antibody drug conjugates (ADCs) immunotherapies Merck +1

Merck and Japanese start-up launch collaboration

Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications

15-Dec-2022 - Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for ...

adeno-associated virus vectors gene therapy viral vectors

Merck acquires Erbi Biosystems

Allows Merck to offer full range of bioreactors, from 2ml to 2000L

08-Dec-2022 - Merck has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”. The deal strengthens Merck’s upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2ml to 2000L ...

acquisitions bioreactors Merck +2

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology

Merck shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity

22-Nov-2022 - To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an ...

cancer drug discovery immunology +4

Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity

Responds to growing global demand for biosafety testing as essential requirement for drug development and commercialization

17-Nov-2022 - Merck invests more than €290million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental ...

biosafety drug development drug safety +1

Merck Confirms Guidance for 2022 and Delivers Strong Organic Growth in Q3

Merck continued to grow despite a challenging external operating environment

10-Nov-2022 - Group sales increased by 16.8% to €5,806 million. The “Big 3” – Process Solutions and Life Science Services, new Healthcare products as well as Semiconductor Solutions – were the key drivers of the strong, 7.1% organic increase in sales. Despite higher costs for raw materials, energy and ...

Merck quarterly reports

Merck Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in China

Reduces animal testing through molecular-based technology

08-Nov-2022 - Merck announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. Utilizing Merck’s Blazar® Rodent Panel, Biotheus’ turn-around-time (TAT) of its cell line characterization reduced from around 60 days to 14 days. “The ...

animal experiments biologics biosafety +2